Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta in Advanced and Metastatic Hepatoma
NCT00191412Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Jan 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00191412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191412.